



(51) International Patent Classification:

C08G 73/02 (2006.01) *C08L 79/02* (2006.01)
A61K 47/34 (2006.01) *C07D 263/10* (2006.01)
A61K 47/48 (2006.01) *C07D 265/08* (2006.01)

(21) International Application Number:

PCT/NL2012/050933

(22) International Filing Date:

28 December 2012 (28.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/NL2012/050001
2 January 2012 (02.01.2012) NL
12159986.4 16 March 2012 (16.03.2012) EP

(71) Applicants: **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, BE-9000 Gent (BE). **BENDER ANALYTICAL HOLDING B.V.** [NL/NL]; Beukstraat 73, NL-3581 XE Utrecht (NL).

(72) Inventor: **HOOGENBOOM, Richard**; Dixielandkade 2, NL-4533 AB Terneuzen (NL).

(74) Agent: **BOT, David**; J.W. Frisolaan 13, NL-2517 JS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2013/103297 A1

(54) Title: POLYOXAZOLINE POLYMERS AND METHODS FOR THEIR PREPARATION, CONJUGATES OF THESE POLYMERS AND MEDICAL USES THEREOF

(57) Abstract: The present invention relates to functionalized poly(2-oxazoline) polymers, which are very suitable as a carrier and/or delivery vehicle (conjugate) of drugs, such as small therapeutic molecules and bio-pharmaceuticals. These polymers are characterized in that they comprise repeating units that are represented by the following formula $-[N(R^1)-(CHR^2)_m]-$ wherein R^1 is $R^3-(CHR^4)_n-CONH-R^5$; R^2 is selected from H and optionally substituted C_{1-5} alkyl; R^3 is CH_2CO , $C(O)O$, $C(O)NH$ OR $C(S)NH$; R^4 is selected from H and optionally substituted C_{1-5} alkyl; R^5 is H; an C_{1-5} alkyl; aryl; or a moiety comprising a functional group that can be used for conjugation; m is 2 or 3 and n is 1-5; or n is 0 and R^3 is CH_2 . The invention relates further to a conjugate of these polyoxazoline polymers with at least one active moiety, such as a therapeutic moiety, a targeting moiety and/or diagnostic moiety, and to the use of these conjugates in the therapeutic treatment or prophylactic treatment or diagnosis of a disease or disorder.

**POLYOXAZOLINE POLYMERS AND METHODS FOR THEIR PREPARATION,
CONJUGATES OF THESE POLYMERS AND MEDICAL USES THEREOF**

5 TECHNICAL FIELD OF THE INVENTION

The invention relates to polyoxazoline polymers containing one or more pendant units with an amide group and to a method for preparing such polymers. The invention relates further to a conjugate of these polyoxazoline polymers with at least one active moiety, such
10 as a therapeutic moiety, a targeting moiety and/or diagnostic moiety, and to the use of these conjugates in the therapeutic treatment or prophylactic treatment or diagnosis of a disease or disorder.

BACKGROUND OF THE INVENTION

15

The ever increasing human life span poses a continuous demand to the pharmaceutical and biotechnology market for improving the therapeutic efficacy of drugs. However, there are major drawbacks associated with conventional dosage forms, such as fast renal clearance of small drugs and enzymatic degradation of biopharmaceuticals.

20

Common problems encountered in the use of small molecule drugs, especially for anti-tumor therapeutics, are their low solubility, rapid excretion and untargeted systemic biodistribution leading to severe toxic side effects.

25

Although more and more biopharmaceuticals are in development, many of these pharmaceuticals have problems that are typical of polypeptide therapeutics, such as short circulating half-life, immunogenicity, proteolytic degradation, and low solubility.

30

Several strategies have emerged as ways to improve the pharmacokinetic and pharmacodynamic properties of pharmaceuticals. Examples of such strategies are; manipulation of the amino-acid sequence of biopharmaceuticals to decrease immunogenicity and proteolytic cleavage; fusion or conjugation of small molecules or biopharmaceuticals to immunoglobulines and serum proteins, such as for example albumin; incorporation of
pharmaceuticals into drug delivery vehicles for protection and slow release; and conjugating
to natural or synthetic polymers.

The most commonly used polymer conjugation strategy is the coupling of poly(ethylene glycol) (PEG) to the small molecule pharmaceutical or bio-pharmaceutical.

Important precedents of PEGylation already demonstrated improved therapeutic efficacies leading to commercial applications of PEGylated bio-pharmaceuticals, such as enzymes, cytokines and antibodies, as well as a PEGylated liposome carriers for the anticancer drug Doxorubicin.

5 PEG is an attractive polymer for drug conjugation since it increases the hydrodynamic radius of a drug and shields it, at least partially, from interactions with the body, including the immune system and proteolytic enzymes. Especially this latter shielding property is the main driving force for the success of PEG, compared to many other water soluble polymers, which is believed to result from the good hydration of PEG. By increasing the molecular weight of a
10 molecule through PEGylation, several significant pharmacological advantages over the unmodified form arise, such as an improved drug solubility, extended circulating half-life, reduced immunogenicity, increased drug stability and an improved protection against proteolytic degradation.

Despite the common use of PEGylation there are several disadvantages associated
15 with its use. Sometimes, hypersensitivity and the formation of PEG antibodies is observed. It is also observed that when PEG with high molecular weights is used, it accumulates in the liver, leading to the so called macromolecular syndrome. The chain length of the PEG molecules may be reduced under the influence of enzymes, such as P450 or alcoholdehydrogenase, giving rise to toxic side products.

20 With respect to small therapeutic molecules it is often observed that with PEG only a relatively low drug loading can be achieved due to the presence of merely one or two hydroxyl terminal groups that can be activated. Furthermore, orthogonal functionalization of PEG or PEG dendrons with the therapeutic moiety, detection moiety or targeting moiety is not readily possible.

25 Furthermore, it is relatively difficult and hazardous to prepare PEG as explosive and highly toxic condensed ethylene oxide monomers are required. In addition, PEG has a limited storeability, i.e. an antioxidant is required for storage in order to avoid peroxide formation.

GB 1 164 582 describes a polyalkylenimine/polycarbonamide graft copolymer having as the backbone a linear polyimine wherein the imino nitrogen atoms are separated on the
30 average by no more than 5 carbon chain atoms, having pendant from some or all of such nitrogen atoms polycarbonamide side chains having as repeating unit a carbonamido divalent radical with a chain of 3 to 18 carbon atoms between the amido nitrogen atom and the carbonyl group, said side chains having a number average molecular weight of at least 500.

WO 2009/112402 describes a heterofunctional polyoxazoline derivative of the general structure: $R_1-\{[N(COX)CH_2CH_2]_o-[N(COR_2)CH_2-CH_2]_n-[N(COY)CH_2-CH_2]_m\}_a-Z$

wherein:

- R_2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, an unsubstituted or substituted alkenyl, an unsubstituted or substituted aralkyl or an unsubstituted or substituted heterocyclalkyl group;
- X is a pendent moiety containing a first functional group;
- Y is a pendent moiety containing a second functional group;
- and m are each an integer independently selected from 1-50;
- n is an integer selected from 0-1000.

WO 2009/112402 describes a random copolymer of linear polyethylenimine comprising two monomeric units, including a monomeric unit comprising a pendant moiety having the following formula: $-CH_2CHR^1CONHCHR^aR^b$;

wherein:

- R^1 represents a hydrogen atom or a C_1 - C_6 alkyl group,
- R^a represents CH_2 -imidazole;
- R^b represents $COOR^2$;
- R^2 represents a hydrogen atom, a C_1 - C_6 alkyl, aryl or aralkyl group, in which the alkyl group is a C_1 - C_6 alkyl,

n is a number comprised between 1 and 99% of the total monomers and

m is a number comprised between 1 and 99% of the total monomers.

The international patent application also describes target molecule-polyoxazoline conjugates comprising a target molecule wherein the target molecule is a therapeutic moiety, a diagnostic moiety or a targeting moiety.

JP 2005161698 describes a recording material that is formed by providing a recording layer including an acylhydrazide compound and a diazo compound. The Japanese application contains a formula A40 that represents a 2-substituted oxazoline, wherein the 2-substituent is represented by $-CH_2-CONH-NHX$, wherein X is a p-substituted benzyl group.

Zarka et al. (*Amphiphilic Polymer Supports for the Asymmetric Hydrogenation of Amino Acid Precursors in Water*, Chem. Eur. J. 2003, 9, 3228-3234) describe the synthesis of amphiphilic, water-soluble diblock copolymers based on 2-oxazoline derivatives with pendent (2S,4S)-4-diphenylphosphino-2-(diphenylphosphinomethyl) pyrrolidine units in the hydrophobic block. The synthetic strategy involves the preparation of a diblock copolymer

precursor with ester functionalities in the side chain; which were converted into carboxylic acids in a polymer-analogous step and finally reacted with the PPMligand in the presence of dicyclohexylcarbodiimide yielding an tertiary amide linkage in between the polymer and the ligand.

5 Cesana et al. (*First Poly(2-oxazoline)s with Pendant Amino Groups*, *Macromol. Chem. Phys.* 2006, 207, 183–192) describe the preparation of a poly(2-oxazoline) with pendant amino groups starting from 2-oxazoline monomer with a Boc protected amino function, 2-[N-Boc-5-aminopentyl]-2-oxazoline (Boc-AmOx). This monomer could be converted via living cationic ring-opening polymerization to homopolymer. After quantitative
10 deprotection, poly(2-oxazoline)s with pendant amino functions were obtained. Copolymerization with different monomer ratios of Boc-AmOx and 2-ethyl-2-oxazoline (EtOx) was performed. A cross-linking reaction with a bifunctional isothiocyanate (Ph(NCS)₂) resulted in poly(2-oxazoline) hydrogels.

 Luxenhofer (Thesis: *Novel Functional Poly(2-oxazoline)s as Potential Carriers for*
15 *Biomedical Applications*, Technische Universität München (2007)) describes a poly(2-oxazoline) comprising 20 units of 2-methyl-2-oxazoline and 5 units of 2-aminoethyl-2-oxazoline. This polymer was cross-linked with hexamethylene diisocyanate to produce an amine hydrogel.

 Liu et al. (*Shell Cross-Linked Micelle-Based Nanoreactors for the Substrate-Selective*
20 *Hydrolytic Kinetic Resolution of Epoxides*, *J. Am. Chem. Soc.* 2011, 133, 14260–14263) describe amphiphilic poly(2-oxazoline) triblock copolymers. These copolymers are prepared from a monomer mixture that includes a cinnamate-functionalized oxazoline monomer that was prepared by a five step synthetic procedure yielding a 2-oxazoline monomer with a C₁₁ spacer in between the monomer ring and the cinnamate.

25 The polyoxazoline polymers with pendant amine containing units reported by Cesana et al. and Luxenhofer suffer from the disadvantage that the amine groups need to be protected. Furthermore, these protected amine-groups tend to interfere with the polymerization process, yielding rather poorly defined polymers. This latter disadvantage can be overcome by replacing the common initiators with a preformed oxazolinium triflate
30 initiating moiety further complicating the polymerization process.


 Conversion of the pendant amines in the aforementioned polyoxazoline polymers into an amide moiety yields functionalized polymers similar to those described by Liu et al.. A disadvantage of these amide-containing polymers is that a primary amine is retained after hydrolysis, i.e. biodegradation, giving rise to toxic polymers.

In view of the problems mentioned above a need exists for polymers with excellent conjugating properties, causing less side effects and providing excellent delivery of small therapeutic molecules and biopharmaceuticals to the tissue involved. In addition, there is a need for a simple process for synthesizing these polymers in good yield and in a well-defined form.

SUMMARY OF THE INVENTION

The present invention relates to functionalized poly(2-oxazoline) polymers, which are very suitable as a carrier and/or delivery vehicle (conjugate) of drugs, such as small therapeutic molecules and bio-pharmaceuticals.

These polymers are characterized in that they comprise repeating units that are represented by the following formula



wherein

- R^1 is $R^3-(CHR^4)_n-CONH-R^5$;
- R^2 is selected from H and optionally substituted C_{1-5} alkyl;
- R^3 is CH_2 , CO, $C(O)O$, $C(O)NH$ or $C(S)NH$;
- R^4 is selected from H and optionally substituted C_{1-5} alkyl;
- R^5 is H; an C_{1-5} alkyl; aryl; or a moiety comprising a functional group that can be used for conjugation;
- m is 2 or 3; and
- n is 1-5; or n is 0 and R^3 is CH_2 .

The polymers of the present invention provide a number of beneficial properties:

- a large number of reactive moieties can be incorporated into the polymer via the side chains R^1 ;
- a hydrophilic amide group is introduced in the side chain enhancing the solubility of the polymers compared to other side-chain functionalized polyoxazolines;
- it is possible to orthogonally functionalize the chain ends as well as the side chains of the polymer, meaning that it is possible to formulate conjugates that simultaneously carry a drug, a targeting moiety and/or a label for imaging;

- mechanical properties of the polymer can be controlled effectively by manipulating the level and the nature of the side chains R^1 ;
- due to its hydrophilic/hydrophobic balance, the polymer can be soluble in organic fluids like ethanol and dichloromethane as well as in water;
- 5 • the polymer has excellent amorphous properties with a glass transition temperature markedly higher compared to, for instance, polyethylene glycol;
- the polymer has film forming capabilities and is easy to plasticize with limited amounts of plasticizers;
- unlike PEG, the polymer may be co-polymerized, allowing the preparation of polymers
10 with a wide range of properties;
- the polymers in which R^5 is H or C_{1-5} alkyl are highly water-soluble and can advantageously be used to improve the blood half life of conjugates;
- the biodegradability of the secondary amide side chains allows release of side chain conjugated moieties.

15

The polymers of the present invention offer the important advantage that solubility, mechanical properties, biodegradability and loading of the polymer with active moieties can be manipulated within broad margins. Thus, the present polymer enables the preparation of a wide range of polymer carriers and polymer conjugates.

20

The invention further relates to conjugates of the aforementioned polymers with drugs, such as small therapeutic molecules and bio-pharmaceuticals. Also targeting moieties and diagnostic moieties may advantageously be conjugated with the presented polymer. The conjugates according to the present invention have amongst others a very good solubility, a
25 tunable blood clearance profile and provide excellent protection against proteolytic degradation.

The present invention also relates to the use of the aforementioned conjugates in therapeutic treatment, prophylactic treatment or diagnosis. It particularly relates to the use in the
30 treatment, prophylactic treatment or diagnosis of cancer.

Finally, the present invention also provides a method for preparing the polymers and conjugates described above.

DEFINITIONS

5 The term “amine” as used herein refers to a group comprising a nitrogen atom that is covalently bonded to at least one carbon, hydrogen or heteroatom.

10 The term “oxyamine” as used herein refers to a group comprising a nitrogen atom and an oxygen atom that are covalently bonded to each other as well as at least one carbon, hydrogen or heteroatom.

15 The term “thiol” as used herein refers to a group comprising a sulfur atom that is covalently bonded to at least one carbon or hydrogen atom.

20 The term “phosphine” as used herein refers to a group comprising a phosphorus atom that is covalently bonded to at least one carbon, oxygen or hydrogen atom.

The term “alkyne” as used herein refers to a group comprising a carbon-carbon triple bond.

25 The term “alkene” as used herein refers to a group comprising with a carbon-carbon double bond.

The term “aryl” as used herein refers to aromatic groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, triazine, dichlorotriazine, tetrazine, pyridine, pyrazine, pyridazine, and pyrimidine.

The term “aldehyde” as used herein refers to groups with a terminal COH moiety.

30 The term “ketone” as used herein refers to groups with a CC(O)C moiety.

The term “acetal” as used herein refers to groups with two single bonded oxygen atoms attached to the same carbon atom, such as, for example, a ketal group.

The term "ester" as used herein refers to groups with a CC(O)OC moiety.

The term "carboxylic acid" as used herein refers to groups with a CC(O)H moiety.

5 The term "carbonate" as used herein refers to groups with a COC(O) OC moiety.

The term "hydroxyl" as used herein refers to groups with an OH moiety.

The term "ether" as used herein refers to groups with a COC moiety.

10

The term "chloroformate" as used herein refers to groups with a COC(O)Cl moiety.

The term "azide" as used herein refers to groups with a NNN moiety.

15 The term "vinyl sulfone" as used herein refers to groups with a $\text{S(O}_2\text{)C=C}$ moiety.

The term "maleimide" as used herein refers to groups with a 2,5-pyrroledione moiety.

The term "isocyanate" as used herein refers to groups with a N=C=O moiety.

20

The term "isothiocyanate" as used herein refers to groups with a N=C=S moiety.

The term "epoxide" as used herein refers to groups with a three membered ring-structure comprising two carbon atoms and an oxygen atom, such as, for example, a glycidyl group.

25

The term "orthopyridyl sulfide" as used herein refers to groups with an S-S-2-pyridine moiety.

The term "sulfonate" as used herein refers to groups with a $\text{S(O)}_2\text{O}$ moiety.

30

The term "haloacetamide" as used herein refers to groups with a $\text{NHC(O)CH}_2\text{X}$ moiety with $\text{X} = \text{Cl, Br or I}$.

The term "haloacetic ester" as used herein refers to groups with a $\text{OC(O)CH}_2\text{X}$ moiety with $\text{X} = \text{Cl, Br or I}$.

The term "hydrazone" as used herein refers to groups with a C(O)N-N moiety.

5

The term "anhydride" as used herein refers to groups with a C(O)OC(O) moiety.

Whenever reference is made to a particular group, such as an alkyl group, unless indicated otherwise this group may be linear or branched.

10

The term "therapeutic moiety" as used herein refers to a compound having, attached to or separated from the polymer, pharmaceutically active properties.

The term "targeting moiety" as used herein refers to a moiety that, attached to or separated from the polymer, is able to bind to specific receptors or proteins in the body.

15

The term "diagnostic moiety" as used herein refers to compounds that, attached to or separated from the polymer, are able to be detected from outside the body.


The term "small molecule", "small therapeutic molecule" or "small molecule drug" as used herein refers to a pharmaceutically active compound having a molecular weight, which is generally lower than 800 daltons and which compound is not a protein, peptide, oligonucleotide or fragment thereof.

The term "bio-pharmaceutical" as used herein refers to a pharmaceutically active compound having a molecular weight which is generally more than 800 daltons. However, these terms also encompass proteins, peptides, oligonucleotides and fragments thereof with a molecular weight lower than 800 daltons.

30

DETAILED DESCRIPTION OF THE INVENTION

A first aspect of the present invention relates to a polymer which comprises repeating units that are represented by the following formula (I)



wherein

- R^1 is $R^3-(CHR^4)_n-\text{CONH}-R^5$;
- R^2 is selected from H and optionally substituted C_{1-5} alkyl;
- 5 • R^3 is CH_2 , CO, $\text{C}(\text{O})\text{O}$, $\text{C}(\text{O})\text{NH}$ or $\text{C}(\text{S})\text{NH}$;
- R^4 is selected from H and optionally substituted C_{1-5} alkyl;
- R^5 is H; an C_{1-5} alkyl; aryl; or a moiety comprising a functional group selected from an amine, an oxyamine, a thiol, a phosphine, an alkyne, an alkene, an aryl, an aldehyde, a ketone, an acetal, an ester, a carboxylic acid, a carbonate, a chloroformate, a hydroxyl, an ether, an azide, a vinyl sulfone, a maleimide, an isocyanate, an isothiocyanate, an epoxide, an orthopyridyl disulfide; a sulfonate; a haloacetamide; a haloacetic acid; a hydrazone; and an anhydride;
- 10 • m is 2 or 3; and
- n is 1-5; or n is 0 and R^3 is CH_2 .

15

In a preferred embodiment of the present invention R^2 is H or C_{1-2} alkyl. Most preferably, R^2 is H.

20 In accordance with one embodiment of the invention R^3 is CO. Polymers in which R^3 is CO can suitably be produced by means of cationic polymerization of 2-oxazoline monomers.

Alternatively, such polymers may suitably be produced from poloxazoline by removing the sidechains to produce a poly[2-alkyl-2-oxazoline/ethylene imine] followed by reaction with an activated ester, such as an acid chloride, or anhydride.

25 According to another embodiment, R^3 is CH_2 . These polymers may suitably be produced from poloxazoline by removing the sidechains to produce a poly[2-alkyl-2-oxazoline/ethylene imine] followed by alkylation.

30 According to another embodiment, R^3 is $\text{C}(\text{O})\text{O}$. These polymers may suitably be produced from poloxazoline by removing the sidechains to produce a poly[2-alkyl-2-oxazoline/ethylene imine] followed by reaction with an activated carbonate, such as chloroformate.

According to another embodiment, R^3 is C(O)NH. These polymers may suitably be produced from poloxazoline by removing the sidechains to produce a poly[2-alkyl-2-oxazoline/ethylene imine] followed by reaction with an isocyanate.

- 5 According to another embodiment, R^3 is C(S)NH. These polymers may suitably be produced from poloxazoline by removing the sidechains to produce a poly[2-alkyl-2-oxazoline/ethylene imine] followed by reaction with an isothiocyanate.

R^4 is preferably selected from H and C_{1-3} alkyl. Most preferably, R^4 is H.

10

In accordance with another preferred embodiment R^5 is a moiety comprising a functional group selected from amine, thiol, hydrazine, aldehyde, activated ester, maleimide or orthopyridyl disulfide. These functional groups are particularly preferred as they are able to bind covalently to a therapeutic moiety, both small molecules and bio-pharmaceuticals, but
15 will be cleaved after having reached cancerous tissue due to the acidic tumor micro-environment, thereby releasing the therapeutic moiety.

15

It is particularly preferred to use an amine as the functional group. One of the major advantages of using an amine as functional group is that such tertiary amines are cationic
20 when present in an aqueous solution, which enables them to interact with RNA and DNA of for example tumor cells. If an amine is used as a functional group it is particularly advantageous when R_3 is CH_2 .

20

In a preferred embodiment of such a polymer, R^5 represents $R^6NR^{7'}R^{7''}$, wherein R^6
25 represents a covalent bond or an optionally substituted C_{1-5} alkylene; and $R^{7'}$ and $R^{7''}$ are independently selected from H and C_{1-5}

25

In accordance with a particularly preferred embodiment R^6 is selected from a covalent bond, methylene, ethylene and propylene for reasons that these polymers display the highest
30 solubility in water.

30

In accordance with another preferred embodiment R^5 is H or C_{1-3} alkyl. Even more preferably, R^5 is H or methyl, most preferably R^5 is methyl.

In a further preferred embodiment of the present invention the integer m in formula (I) is 2.


The integer n preferably is 1-5, even more preferably 1-4 and most preferably 1-2.

- 5 The polymer according to the present invention typically has a molecular weight of at least 1,000 g/mol. Even more preferably, the polymer has a molecular weight in the range of 2,000-100,000 g/mol, most preferably of 5,000-50,000 g/mol.

- 10 In case R⁵ is a moiety comprising a functional group as specified herein, the repeating units represented by formula (I) typically represents at least 2 mol%, more preferably 5-70 mol.% and most preferably 10-30 mol.% of the polymer.

- 15 In case R⁵ is H or C₁₋₅ alkyl the repeating units represented by formula (I) typically represents at least 10-100 mol%, more preferably 20-100 mol.% and most preferably 40-100 mol.% of the polymer.

- Besides the (monomeric) repeating units represented by formula (I), the present polymer may suitably contain other repeating units, notably other cyclic imino ether units, such as 2-oxazolines and 2-oxazines. In a particularly preferred embodiment of the present invention the polymer contains 0-98 mol.%, more preferably 30-95 mol.% and most preferably 70-90 mol% of repeating units represented by the formula (Y)



- 25 wherein R^a represents C(O)H, C(O)R^k or R^k, and wherein R^k represents optionally substituted C₁₋₂₂ alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl, and wherein the integer m is 2 or 3.

Preferably, R^k, represents an optionally substituted C₁₋₂₂ alkyl, more preferably C₁₋₁₀ alkyl and most preferably C₁₋₅ alkyl.

- 30 Repeating units represented by formula (I) and repeating units represented by formula (Y) together typically represent at least 50 wt.% of the present polymer. Even more preferably said repeating units together represent at least 80 wt.% and most preferably 100 wt.% of the repeating units contained in the present polymer.

The polymer according to the present invention may be a homopolymer or a copolymer. Most preferably, the present polymer is a poly-oxazoline copolymer.

It is further preferred that the polymer according to the present invention is a linear polymer.

5

A second aspect of the present invention relates to a conjugate of a polymer as described above, and at least one active moiety selected from a therapeutic moiety, a targeting moiety and a diagnostic moiety.

10 Preferably, the conjugate is obtained by allowing the active moiety, such as a therapeutic moiety, targeting moiety and/or diagnostic moiety to react with at least one of the functional groups in R⁵ of the polymer. Advantageously, the active moiety is covalently bonded to the polymer.

15 Alternatively, the conjugate is a non-covalent assembly based on multiple non-covalent interactions such as hydrogen bonding or electrostatic interactions (e.g. involving tertiary amines within the polymer) with either complementary hydrogen bonding or oppositely charged macromolecules, including synthetic polymers, biopolymers and biopharmaceutics. In a preferred embodiment, conjugate is a layer-by-layer assembly of the polymer and a
20 macromolecule. In another preferred embodiment, the conjugate is an assembly in the form of a non-viral vector for gene delivery.

The therapeutic moiety that is contained in the present conjugate preferably is able to inhibit a signal transduction cascade in a cellular system, interferes with the cytoskeleton or
25 intercalates in the DNA double helix. It is further preferred that the therapeutic moiety, attached to or separated from the polymer, has anti-fibrotic, anti-angiogenic, anti-tumor, immune-stimulating or apoptosis-inducing activity. Particularly preferred therapeutic moieties are doxorubicin, daunorubicin, epirubicin, paclitaxel, mesochlorin, 5-fluorouracil and cis-platin.

30

The targeting moiety that is contained in the conjugate preferably comprises a folate group, since it is known that folate has a natural high affinity for the folate receptor protein, which is commonly expressed on the surface of many human cancers. Another preferred targeting moiety is the arginine-glycine-aspartate (RGD) sequence, as it targets integrin that is also

overexpressed in cancerous tissues. The targeting moieties according to the present invention may also comprise antibodies, fragment-antigen-binding fragments (FABs), single domain antibodies (nanobodies), peptides or oligonucleotides, such as RNA, DNA and siRNA.

- 5 The diagnostic moiety is preferably selected from radiolabels (radionuclides), PET-imageable agents, SPECT-imageable agents, MRI-imagable agents and fluorescent probes.

A third aspect of the present invention relates to the above mentioned conjugate for use in the therapeutic treatment, prophylactic treatment or diagnosis of diseases or disorders,
10 particularly cancer.

In accordance with a particularly preferred embodiment of said use, the conjugate is administered intravenously, subcutaneously or orally. Most preferably, the conjugate is administered subcutaneously or orally.

15

A fourth aspect of the present invention relates to a method of preparing a polymer as described above, wherein the method comprises:

- providing a polymer comprising repeating units that are represented by the following formula (II)

20
$$-[N(R^1)-(CHR^2)_m]- \quad (\text{formula II})$$

wherein:

- R^1 is $R^3-(CHR^4)_n-COOR^8$;
 - R^2 , R^3 , R^4 , m and n have the same meaning as described herein before;
 - R^8 is selected from optionally substituted C_{1-22} alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, and optionally substituted aryl,
- 25

- reacting said polymer with an amine compound represented by the following formula (III)

$$NH_2-R^5 \quad (\text{formula III})$$

wherein:

- R^5 has the same meaning as above.

30

In a preferred embodiment of the this method R^8 is a C_{1-3} alkyl. Most preferably, R^8 is a methyl group.

In accordance with one embodiment of the present method R^3 is CO or C(O)O and the polymer comprising repeating units that are represented by formula (II), is obtained by :

- hydrolysing a polymer comprising repeating units that are represented by the following formula (IV)



to produce a polymer comprising hydrolyzed repeating units that are represented by the following formula (V)



- reacting the polymer comprising hydrolyzed repeating units with an ester represented by the following formula (VIa)



or the following formula (VIb)




- wherein X' is selected from Cl, Br, I, OH or OR^9 where R^9 is an activating moiety, such as N-hydroxysuccinimide, para-nitrophenyl or pentafluorophenyl.

According to another advantageous embodiment of the present method, R^3 is CH_2 , C(O)NH or C(S)NH and the polymer comprising repeating units that are represented by formula (II) is obtained by:

- hydrolysing a polymer comprising repeating units that are represented by the following formula (IV)




to produce a polymer comprising hydrolyzed repeating units that are represented by the following formula (V)



- reacting the polymer comprising hydrolyzed repeating units with an ester represented by the following formula (VIIa)



or the following formula (VIIb)




wherein X'' is selected from Cl, Br, I, or an activated alcohol, such as triflate, tosylate, mesylate and nosylate;

or the following formula (VIIc)




or the following formula (VIId)



5 In accordance with yet another embodiment of the present method R^3 is CO, and the polymer comprising repeating units that are represented by formula (II) is obtained by:

- ring-opening polymerization of 2-substituted 2-oxazoline or a 2-substituted dihydro-1,3-oxazine represented by the following formula (VIII)



10 wherein R^c represents a 2- substituted oxazoline or a 2-substituted dihydro-1,3-oxazine.

According to yet a further embodiment of the invention R^3 is CO and the polymer comprising repeating units that are represented by formula (II) is obtained by:

- ring-opening polymerization of 2-substituted oxazoline or a 2-substituted dihydro-1,3-oxazine represented by the following formula (IX)



15 wherein R^c represents a 2-oxazoline or a 2-dihydro-1,3-oxazine, and wherein $\text{R}^{5'}$ is a group R^5 as defined herein before, said group being protected by protecting groups; and

- removing the protecting groups from $\text{R}^{5'}$.

20

Another aspect of the invention relates to a 2-substituted oxazoline or a 2-substituted dihydro-1,3-oxazine, wherein the 2-substituent is represented by the following formula (X)



wherein R^4 , R^5 and n are defined as herein before.

25

According to a particularly preferred embodiment of the aforementioned 2-substituted oxazoline or 2-substituted dihydro-1,3-oxazine R^5 is H or an C_{1-5} alkyl.

The invention is further illustrated by means of the following non-limiting examples.

30

EXAMPLES

Example 1

5 A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

Aquazol 50 (poly(2-ethyl-2-oxazoline) (PEtOx), Mw 50,000) was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer. Twelve percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

10

This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl succinyl chloride, followed by the reaction of the methyl ester with ethylenediamine (30 equivalents in the absence of solvent) to yield an amine-side chain activated poly[2-(ethyl/amino-ethyl-amido-ethyl)-2-oxazoline] copolymer.

15

Example 2

A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

20 Aquazol 50 (PEtOx, Mw 50,000) was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer. Ten percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

25 This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl bromoacetate, followed by the reaction of the methyl ester with ethylenediamine (30 equivalents in the absence of solvent) to yield an amine-side chain activated poly[(2-ethyl-2-oxazoline)/(amino-ethyl-amido-methyl)] copolymer.

Example 3

30 A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

Aquazol 50 (PEtOx, Mw 50,000) was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer. Ten percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

5 This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl acrylate, followed by the reaction of the methyl ester with ethylenediamine (30 equivalents in the absence of solvent) to yield an amine-side chain activated poly[(2-ethyl-2-oxazoline)/(amino-ethyl-amido-ethyl)] copolymer.

10 Example 4

A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

2-(2-Methoxycarbonylethyl)-2-oxazoline was prepared following a literature procedure (A. Levy, M. Litt, J. Polym. Sci. A 1968, 6, 1883) followed by cationic ring-opening polymerization yielding the corresponding methylester functionalized homopolymer, poly(2-(2-methoxycarbonylethyl)-2-oxazoline).

20 Copolymerization of the 2-(2-methoxycarbonylethyl)-2-oxazoline monomer with 2-ethyl-2-oxazoline (50%) or 2-methyl-2-oxazoline (50%) yielded statistical copolymers.

These polymers were functionalized by the reaction of the methyl ester side chains with ethylenediamine (30 equivalents in the absence of solvent) to yield amine-side chain activated poly[amino-ethyl-amido-ethyl] copolymers.

25

Example 5

The poly(2-(2-methoxycarbonylethyl)-2-oxazoline) homopolymer from Example 4 was reacted with N-boc amino ethane amine by dissolving 0.8 g polymer in 2.5 mL N-boc amino ethane amine followed by 23 hours stirring at 80 °C. ¹H NMR spectroscopy in CDCl₃ revealed that ~ 90% of the methyl ester units were converted into Boc-aminoethyl amido side chains. This polymer was further reacted with hydrochloric acid (HCl) by dissolving 850 mg of polymer in dichloromethane (30 mL), which was added dropwise to a HCl solution in ethyl acetate (0.175 mL, 2.98 mmol). After complete addition, the solution was stirred for 6 hours at room temperature. ¹H NMR demonstrated the successful formation of the

hydrochloric acid salt of amino-ethyl amido side chain functionalized polymer by disappearance of the Boc signal at 1.4 ppm.

Example 6

- 5 A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

Poly(2-ethyl-2-oxazoline) (PEtOx, Mw 10,000, degree of polymerization 100), prepared by living cationic ring-opening polymerization under microwave irradiation (140 °C, 4 M
10 monomer concentration in acetonitrile, methyl tosylate as initiator), was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer. Eighteen percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by
15 first coupling of methyl succinyl chloride yielding the methyl ester side-chain functionalized copolymer. Infrared (IR) spectroscopy clearly revealed the appearance of the characteristic methyl ester band at 1732 cm⁻¹ while proton nuclear magnetic resonance (¹H NMR) spectroscopy clearly showed the methyl ester signal at 3.7 ppm.

- 20 This polymer was further modified by reaction with various amines (at least 10 fold excess) in bulk, except hydrazine that was added as hydrazine mono-hydrate, at 70 °C in a closed reaction vessel. Successful coupling of the amine and the formation of the side chain amide substituents was demonstrated by the disappearance of the peak of the methyl ester at 3.7 ppm in the ¹H-NMR spectra. Furthermore, new signals were detected for the incorporated
25 amide side chains between 7 and 9 ppm when the measurements were conducted in DMSO-d₆. Furthermore, the resulting polymers revealed a higher molar mass by size exclusion chromatography compared to the starting polymer that had a weight average molar mass (M_w) of 1.78*10⁴, a number average molar mass (M_n) of 1.67*10⁴ and a dispersity (Đ) of 1.1. Finally, IR spectroscopy revealed the disappearance of the band at 1732 cm⁻¹ while a
30 secondary amide band (N-H bending vibration) appeared at 1570-1515 cm⁻¹. An overview of these reactions is provided in Table 1.

Table 1

Amine	¹ H-NMR (ppm) ¹	M _w (x10 ⁴) ²	M _n (x10 ⁴) ²	Đ ²
Methylamine	5.9	1.95	1.77	1.1
Ethylamine	7.8	1.95	1.77	1.1
Propylamine	7.9	1.95	1.78	1.1
Dimethylamine	6.3	1.95	1.78	1.1
Hydrazine-monohydrate	9	1.95	1.77	1.1
Leucine	n.d. ³	2.03	1.8	1.1
Glycine	n.d. ³	2.10	1.8	1.1
Aminoethanol	n.d. ³	2.38	2.2	1.1
Allylamine	8.4	1.8	1.65	1.1
1-amino-3-butyne	8.4	1.79	1.67	1.1
N,N'-dimethylethylene diamine	8.2	1.81	1.66	1.1

¹ Chemical shift of the resulting amide proton in DMSO-d₆

² Determined by means of size exclusion chromatography calculated against PMMA standards

5 ³ Measurements performed in methanol-d₄ or CDCl₃ did not show this amide signal.

Example 7

A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

10

Poly(2-ethyl-2-oxazoline) (PEtOx, M_w 10,000, degree of polymerization 100), prepared by living cationic ring-opening polymerization under microwave irradiation (140 °C, 4 M monomer concentration in acetonitrile, methyl tosylate as initiator), was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer.

15

Eighteen percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl-3-isocyanatopropionate (3 eq; reaction performed in dry chloroform for 5 minutes at 150 °C in a microwave oven) yielding the methyl ester side-chain

20

functionalized copolymer in which the side chain is attached to the main chain via a urea linkage. Infrared (IR) spectroscopy clearly revealed the appearance of the characteristic methyl ester band at 1732 cm⁻¹ while proton nuclear magnetic resonance (¹H NMR)

spectroscopy clearly showed the methyl ester signal at 3.7 ppm. SEC revealed a M_w of 1.98 x 10⁴, M_n of 1.83 x 10⁴ and a Đ of 1.1.

25

This polymer can be further modified by reaction of the methyl ester with various amines as exemplified in Example 6. This was demonstrated by reaction of the polymer with ethylamine by dissolving 0.3 g polymer in 2 mL ethylamine and heating overnight at 70 °C. The success of the reaction was demonstrated by ¹H NMR spectroscopy in DMSO-d₆ revealing the specific amide signal at 7.9 ppm. IR spectroscopy also confirmed the reaction by disappearance of the band at 1732 cm⁻¹. SEC also confirmed an increase of molar mass after the reaction to a M_w of 2.14 x 10⁴, M_n of 1.98 x 10⁴ and a Đ of 1.1.

Example 8

10 A polyoxazoline polymer according to the present invention was prepared by a method comprising the following steps.

Poly(2-ethyl-2-oxazoline) (PEtOx, M_w 10,000, degree of polymerization 100), prepared by living cationic ring-opening polymerization under microwave irradiation (140 °C, 4 M monomer concentration in acetonitrile, methyl tosylate as initiator), was subjected to controlled acidic hydrolysis to yield a poly[2-ethyl-2-oxazoline/ethylene imine] copolymer. Eighteen percent of the initial 2-ethyl-oxazoline units was hydrolyzed.

This poly[2-ethyl-2-oxazoline/ethylene imine] was functionalized in a two-step approach by first coupling of methyl-3-isothiocyanatopropanoate (3 eq; reaction performed in dry chloroform for 5 minutes at 150 °C in a microwave oven) yielding the methyl ester side-chain functionalized copolymer in which the side chain is attached to the main chain via a urea linkage. Infrared (IR) spectroscopy clearly revealed the appearance of the characteristic methyl ester band at 1732 cm⁻¹ while proton nuclear magnetic resonance (¹H NMR) spectroscopy clearly showed the methyl ester signal at 3.7 ppm. SEC revealed a M_w of 2.28 x 10⁴, M_n of 2.05 x 10⁴ and a Đ of 1.1.

This polymer can be further modified by reaction of the methyl ester with various amines as exemplified in Example 6. This was demonstrated by reaction of the polymer with ethylamine by dissolving 0.3 g polymer in 2 mL ethylamine and heating overnight at 70 °C. The success of the reaction was demonstrated by ¹H NMR spectroscopy in DMSO-d₆ revealing the specific amide signal at 8.1 ppm. IR spectroscopy also confirmed the reaction by disappearance of the band at 1732 cm⁻¹. SEC also confirmed an increase of molar mass after the reaction to a M_w of 2.26 x 10⁴, M_n of 2.08 x 10⁴ and a Đ of 1.1.

Example 9

The poly(2-(2-methoxycarbonylethyl)-2-oxazoline) homopolymer prepared in example 4 is reacted with hydrazine to yield the poly(hydrazone ethyl-2-oxazoline) homopolymer.

5

Example 10

The polymer of Example 1, poly[2-(ethyl/amino-ethyl-amido-ethyl)-2-oxazoline] copolymer, is reacted with doxorubicin by mixing both in an organic solvent, such that a conjugate of the polymer and doxorubicin is formed via an imine linkage (herein after: POX-DOX-conjugate), which linker is acid-cleavable. Such an acid cleavable linker allows a rapid partial cleavage of the doxorubicin from the polymer already after transfer of the conjugate to the interstitial space of the tumor, i.e. extracellularly in close proximity to the target tumor cells, because tumor tissue is generally more acidic than non-tumor tissue. Thus, after save delivery of the conjugated drug to the tumor, the drug is liberated in or close to the tumor to carry out its action in the tumor tissue.

10

15

Example 11

The polymer from Example 9, poly(hydrazone ethyl-2-oxazoline) homopolymer, is reacted with DOX to yield the POX-DOX conjugate in which the DOX is attached to the polymer via a pH cleavable hydrazone linkage.

20

Example 12

The copolymer consisting of ethyl and hydrazide side chains from Example 6, obtained by reaction of the methyl ester side chains with hydrazine, is reacted with DOX to yield the POX-DOX conjugate in which the DOX is attached to the polymer via a pH cleavable hydrazone linkage.

25

Example 13

In order to direct the conjugated oxazoline polymers (POX-DOX-conjugate) of Examples 11 and 12 to the cancerous tissue, the polymers are provided with targeting moieties. A very suitable targeting moiety is folate. Folate targeting is based on the natural high affinity of folate for the folate receptor protein (FR) which is commonly expressed on the surface of many human cancers. As such, folate-drug conjugates also bind tightly to the folate receptor

30

and trigger cellular uptake of the conjugated polymer. Within the tumor tissue, the therapeutic moiety is released due to cleavage of the hydrazone linker.

5 The folate moiety is linked to the POX-DOX-conjugates by coupling of the folate carboxylic acid group to the amine-terminus of the oxazoline polymer (DOX) that is introduced by endcapping of the polymers with potassium phthalimide followed by release of the amine by reaction with hydrazine.

Example 14

10 Besides folate the so called RGD-sequence is also very useful as targeting moiety since it actively targets integrins, which are overexpressed in cancerous tissue. Here the conjugated oxazolines (POX-DOX conjugate) of Examples 11 and 12 are reacted with the cysteine moiety of CRGD using radical thiol-ene coupling to the alkene chain end functionality of the polyoxazoline that is introduced using propene tosylate as initiator.

15

Example 15

¹⁸F labeling of amino-functionalized polyoxazoline is performed by reaction of the amine moieties with 4-nitrophenyl 2-[¹⁸F]fluoropropionate, whereby the nitrophenyl activated ester is coupled to the amine.

20

CLAIMS

1. A conjugate of a polymer and at least one active moiety selected from a therapeutic moiety, a targeting moiety and a diagnostic moiety, said polymer comprising repeating units that are represented by the following formula (I):



wherein:

- R^1 is $R^3-(CHR^4)_n-CONH-R^5$;
- R^2 is selected from H and optionally substituted C_{1-5} alkyl;
- 10 • R^3 is CH_2 , CO, C(O)O, C(O)NH or C(S)NH;
- R^4 is selected from H and optionally substituted C_{1-5} alkyl;
- R^5 is H; an C_{1-5} alkyl; aryl; or a moiety comprising a functional group selected from an amine, an oxyamine, a thiol, a phosphine, an alkyne, an alkene, an aryl, an aldehyde, a ketone, an acetal, an ester, a carboxylic acid, a carbonate, a chloroformate, a hydroxyl, an ether, an azide, a vinyl sulfone, a maleimide, an isocyanate, isothiocyanate, an epoxide, orthopyridyl disulfide, sulfonate, halo acetamide, halo acetic acid, hydrazine, and anhydride;
- 15 • m is 2 or 3; and
- n is 1-5; or n is 0 and R^3 is CH_2 .

20

2. Conjugate according to 1, wherein R^5 is a moiety comprising an amine.

3. Conjugate according to claim 2, wherein R^5 represents $R^6NR^7R^{7'}$, wherein:

- R^6 represents a covalent bond or an optionally substituted C_{1-5} alkylene;
- 25 • R^7 and $R^{7'}$ are independently is selected from H and C_{1-5} .

4. Conjugate according to any one of the preceding claims, wherein the polymer has a molecular weight of 2,000-50,000 g/mol.

- 30 5. Conjugate according to any one of the preceding claims, wherein the repeating units represented by formula (I) represent at least 5 mol.% of the polymer.

6. Conjugate according to any one of the preceding claims, wherein the polymer contains 0-80 wt.% of repeating units represented by formula (X)



wherein R^a represents $C(O)H$, $C(O)R^k$ or R^k , and R^k represents optionally substituted C_{1-22} alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl.

7. Conjugate according to any one of the preceding claims, wherein the conjugate is obtained by reacting the active moiety with at least one of the functional groups in R^5 of the polymer.

8. Conjugate according to any one of the preceding claims for use in therapeutic treatment, prophylactic treatment or diagnosis.

9. A polymer comprising repeating units that are represented by the following formula (I):



wherein:

- R^1 is $R^3-(CHR^4)_n-CONH-R^5$;
- R^2 is selected from H and optionally substituted C_{1-5} alkyl;
- R^3 is CH_2 , CO, $C(O)O$, $C(O)NH$ or $C(S)NH$;
- R^4 is selected from H and optionally substituted C_{1-5} alkyl;
- m is 2 or 3; and
- n is 1-2; or n is 0 and R^3 is CH_2 ; and wherein:
 - in case R^3 is CH_2 , R^5 represents $R^6NR^7R^7$, wherein:
 - R^6 represents a covalent bond or an optionally substituted C_{1-5} alkylene;
 - R^7 and R^7 are independently selected from H and C_{1-5} ; or
 - otherwise, R^5 is H; an C_{1-5} alkyl; aryl; or a moiety comprising a functional group selected from an amine, an oxyamine, a thiol, a phosphine, an alkyne, an alkene, an aryl, an aldehyde, a ketone, an acetal, an ester, a carboxylic acid, a carbonate, a chloroformate, a hydroxyl, an ether, an azide, a vinyl sulfone, a maleimide, an isocyanate, isothiocyanate, an epoxide, orthopyridyl disulfide, sulfonate, halo acetamide, halo acetic acid, hydrazine, and anhydride.

10. Polymer according to 9, wherein R^5 is a moiety comprising an amine.

11. Polymer according to claim 10, wherein R^5 represents $R^6NR^{7'}R^{7''}$, wherein:

- R^6 represents a covalent bond or an optionally substituted C_{1-5} alkylene;
- $R^{7'}$ and $R^{7''}$ are independently is selected from H and C_{1-5} .

12. Polymer according to any one of claims 9-11, wherein the polymer has a molecular weight of 2,000-50,000 g/mol.

13. Polymer according to any one of claims 9-12, wherein the repeating units represented by formula (I) represent at least 5 mol.% of the polymer.

14. Polymer according to any one of claims 9-13, wherein the polymer also contains repeating units represented by formula (Y)



wherein R^a represents $C(O)H$, $C(O)R^k$ or R^k , and R^k represents optionally substituted C_{1-22} alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; and

wherein repeating units represented by formula (I) and repeating units represented by formula (Y) together represent at least 50 wt.% of the polymer.

15. A method of preparing a polymer as defined in any one of claims 1-8 or according to any one of claims 9-14, said method comprising:

- providing a polymer comprising repeating units that are represented by the following formula (II)



wherein:

- R^1 is $R^3-(CHR^4)_n-COOR^8$;
- R^2 , R^3 , R^4 , m and n have the same meaning as in claim 1;
- R^8 is selected from optionally substituted C_{1-22} alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, and optionally substituted aryl,

- reacting said polymer with an amine compound represented by the following formula (III)



wherein:


- R^5 has the same meaning as in claim 1.

5 16. Method according to claim 15, wherein R^3 is CO or C(O)O and wherein the polymer comprising repeating units that are represented by formula (II) is obtained by:


- hydrolysing a polymer comprising repeating units that are represented by the following formula (IV)




10 to produce a polymer comprising hydrolyzed repeating units that are represented by the following formula (V)



- reacting the polymer comprising hydrolyzed repeating units with an ester represented by the following formula (VIa)



or the following formula (VIb)



wherein X^7 is selected from Cl, Br, I, OH or OR^9 wherein R^9 is an activating group selected from N-hydroxysuccinimide, para-nitrophenyl and pentafluorophenyl.


20

17. Method according to claim 15, wherein R^3 is CH_2 , C(O)NH or C(S)NH and wherein the polymer comprising repeating units that are represented by formula (II) is obtained by:


- hydrolysing a polymer comprising repeating units that are represented by the following formula (IV)



to produce a polymer comprising hydrolyzed repeating units that are represented by the following formula (V)



- reacting the polymer comprising hydrolyzed repeating units with an ester represented by the following formula (VIIa)



or the following formula (VIIb)



wherein X⁷ is selected from Cl, Br, I, or an activated alcohol, such as triflate, tosylate, mesylate and nosylate;

or the following formula (VIIc)



5 or the following formula (VIId)



18. Method according to claim 15, wherein R³ is CO, and wherein the polymer comprising repeating units that are represented by formula (II) is obtained by:


- 10 • ring-opening polymerization of 2-substituted 2-oxazoline or 2-substituted dihydro-1,3-oxazine represented by the following formula (VIII)



wherein R^c represents a 2-oxazoline or a 2-dihydro-1,3-oxazine.

15 19. A method of preparing a polymer as defined in any one of claims 1-8 or according to any one of claims 9-14, wherein R³ is CO and wherein the polymer comprising repeating units that are represented by formula (II) is obtained by:

- ring-opening polymerization of 2-substituted oxazoline or a 2-substituted dihydro-1,3-oxazine represented by the following formula (IX)



wherein R^c represents a 2-oxazoline or a 2-dihydro-1,3-oxazine, wherein R⁴ and n are defined as in claim 1, and wherein R^{5'} is a group R⁵ as defined in claim 1, said group R⁵ being protected by protecting groups; and

- removing the protecting groups from R^{5'}.

25

INTERNATIONAL SEARCH REPORT

International application No PCT/NL2012/050933

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C08G73/02 A61K47/34 A61K47/48 C08L79/02 C07D263/10
 C07D265/08
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C08G A61K C08L C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data, COMPENDEX, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/71600 A1 (BASF AG [DE]; MOHR BERNHARD [DE]; FEHRINGER DIETRICH [DE]; BOECKH DIET) 30 November 2000 (2000-11-30)	1,4-8
A	page 3, line 6 - page 4, line 22 page 8, line 34 - page 11, line 33 page 15, line 5 - page 18, line 26 page 21, lines 26-35; claims	2,3,9-19
X	WO 2009/112402 A1 (CENTRE NAT RECH SCIENT [FR]; UNIV ORLEANS [FR]; CHERADAME HERVE [FR];) 17 September 2009 (2009-09-17)	1,4-8
	page 4, line 1 - page 23, line 11; claims; examples	
	----- -/--	

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 25 April 2013	Date of mailing of the international search report 07/05/2013
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Otegui Rebollo, Juan
--	--

INTERNATIONAL SEARCH REPORT

International application No

PCT/NL2012/050933

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 760 311 A (ALLIED COLLOIDS MFG COMPANY LT; RONALD GILL) 31 October 1956 (1956-10-31) page 1, line 11 - page 2, line 14 page 2, lines 66-96 page 3, lines 31-55; claims; example 14 page 10, lines 3-71 page 11, lines 3-43	1-19
A	----- GB 1 164 582 A (ALLIED CHEM [US]) 17 September 1969 (1969-09-17) page 1, line 11 - page 3, line 108; claims; examples	1-19
Y	----- WO 2009/089542 A2 (SERINA THERAPEUTICS INC [US]; HARRIS J MILTON [US]; BENTLEY MICHAEL DA) 16 July 2009 (2009-07-16) page 1, line 10 - page 5, line 30 page 8, line 1 - page 22, line 13; claims	1-14
Y	----- JP 2005 161698 A (FUJI PHOTO FILM CO LTD) 23 June 2005 (2005-06-23) paragraphs [0010], [0023]; claim 3; compounds A-40	1-14
Y	----- RICHTER R ET AL: LIEBIGS ANN. CHEM., vol. 743, 1971, pages 10-24, XP009159097, abstract page 13, last paragraph - page 15, paragraph 3 page 23, paragraph 5	1,4-8
A	----- US 2004/157157 A1 (SAITO NAOKI [JP] ET AL) 12 August 2004 (2004-08-12) paragraphs [0015] - [0017], [0019] - [0035], [0042] - [0057]; claim 19	1-19
A	----- US 3 996 237 A (TOMALIA DONALD A) 7 December 1976 (1976-12-07) column 1, line 28 - column 2, line 64; claims; examples 1,2,6,7	1-19
A	----- DATABASE COMPENDEX [Online] ENGINEERING INFORMATION, INC., NEW YORK, NY, US; 20 September 1988 (1988-09-20), INATA HIROO ET AL: "Postcrosslinking of linear polyesters. II. UV-induced crosslinking agents having carboxyl reactive group", XP009159100, Database accession no. EIX92090229487 abstract table I; compound DAIO	1-19
	-/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/NL2012/050933

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>& JOURNAL OF APPLIED POLYMER SCIENCE 1988 SEP 20, vol. 36, no. 7, 20 September 1988 (1988-09-20), pages 1667-1672, DOI: DOI:10.1002/APP.1988.070360714 -----</p> <p>BENTOLILA A ET AL: "Poly(N-acryl amino acids): a new class of biologically active polyanions", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, 1 January 2000 (2000-01-01), pages 2591-2600, XP002497142, ISSN: 0022-2623, DOI: 10.1021/JM000089J [retrieved on 2000-06-13] the whole document -----</p>	1-19

INTERNATIONAL SEARCH REPORT

International application No

PCT/NL2012/050933

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0071600	A1	30-11-2000	EP 1183298 A1 06-03-2002
			JP 2003500500 A 07-01-2003
			WO 0071600 A1 30-11-2000

WO 2009112402	A1	17-09-2009	CA 2717778 A1 17-09-2009
			EP 2257587 A1 08-12-2010
			FR 2928373 A1 11-09-2009
			US 2011091407 A1 21-04-2011
			WO 2009112402 A1 17-09-2009

GB 760311	A	31-10-1956	NONE

GB 1164582	A	17-09-1969	DE 1720255 A1 09-06-1971
			FR 1562914 A 11-04-1969
			GB 1164582 A 17-09-1969
			US 3442975 A 06-05-1969

WO 2009089542	A2	16-07-2009	CN 101959934 A 26-01-2011
			EP 2235090 A2 06-10-2010
			JP 2011510120 A 31-03-2011
			KR 20110007084 A 21-01-2011
			US 2011009594 A1 13-01-2011
			US 2012136123 A1 31-05-2012
			WO 2009089542 A2 16-07-2009

JP 2005161698	A	23-06-2005	NONE

US 2004157157	A1	12-08-2004	NONE

US 3996237	A	07-12-1976	NONE
